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BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important therapeutic target in oncology, and three
different types of EGFR inhibitors have been approved for the treatment of cancer patients. However, there has been no clear
association between the expression levels of EGFR protein in the tumours determined by the FDA-approved EGFR PharmDx kit
(Dako) or other standard anti-EGFR antibodies and the response to the EGFR inhibitors.
METHOD: In this study, we investigated the potential of our anti-EGFR monoclonal antibodies (mAbs; ICR9, ICR10, ICR16) for
immunohistochemical diagnosis of wild-type EGFR and/or the type-III deletion mutant form of EGFR (EGFRvIII) in formalin-fixed,
paraffin-embedded human tumour specimens.
RESULTS: We found that the anti-EGFR mAb in the EGFR PharmDx kit stained both wild-type and EGFRvIII-expressing cells in
formalin-fixed, paraffin-embedded sections. This pattern of EGFR immunostaining was also found with our anti-EGFR mAb ICR16.
In contrast, mAbs ICR10 and ICR9 were specific for the wild-type EGFR.
CONCLUSION: We conclude that mAbs ICR9 and ICR10 are ideal tools for investigating the expression patterns of wild-type EGFR
protein in tumour specimens using immunohistochemistry, and to determine their prognostic significance, as well as predictive value
for response to therapy with EGFR antibodies.
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The epidermal growth factor receptor (EGFR)/HER1 is a 170-KDa
transmembrane glycoprotein with tyrosine kinase activity and the
prototype of the type-I growth factor receptor (also called HER/
ErbB) family, which can be activated following the binding of
several ligands (EGF, TGFa, amphiregulin, HB-EGF, betacellulin
and epiregulin) to its extracellular domain (Carpenter, 1987;
Modjtahedi and Dean, 1994; Salomon et al, 1995; Gullick, 2001;
Singh and Harris, 2005). Ligand binding induces EGFR homo-
dimerisation or heterodimerisation with other members of the
ErbB family, autophosphorylation of tyrosine residues and
ultimately, activation of several intracellular signalling pathways
(Yarden and Sliwkowski, 2001). Signalling via the EGFR has been
associated with increased cell proliferation, reduced apoptosis,
angiogenesis, invasion and metastasis, and all of which are
hallmarks of cancer (Yarden, 2001; Lui and Grandis, 2002;
Hanahan and Weinberg, 2011). Aberrant expression and activation
of EGFR have been reported in a wide range of epithelial tumours,
and in several studies, have been associated with poor prognosis
and resistance to therapy (Modjtahedi and Dean, 1994; Salomon
et al, 1995; Nicholson et al, 2001).
The EGFR is an important therapeutic target in patients with
metastatic colorectal cancer (mCRC), head and neck cancer, non-
small cell lung cancer and pancreatic cancer (Mendelsohn and
Baselga, 2003; Zhang et al, 2007; Ciardiello and Tortora, 2008;
Modjtahedi and Essapen, 2009). Currently, two classes of EGFR
inhibitors namely monoclonal antibodies (mAbs) and small
molecules, which bind to the extracellular ligand-binding domain
and the intracellular tyrosine kinase domain of the EGFR,
respectively, have been approved for the treatment of cancer
patients (Modjtahedi and Essapen, 2009). Of these, the mAbs
cetuximab and panitumumab have been approved for the
treatment of patients with mCRC in combination with chemotherapy,
and several other anti-EGFR antibodies are currently at
different stages of clinical development (Wong, 2005; Wu et al,
2008). To aid in the identification of CRC patients who are eligible
for treatment with cetuximab and panitumumab, the EGFR status
of the tumours is determined using the FDA-approved EGFR
PharmDx immunohistochemistry kit (Dako, Cambridge, UK;
Mitchell, 2004; Bhargava et al, 2006; Buckley and Kakar, 2007;
Ensinger and Sterlacci, 2008). However, although treatment with
these agents improve survival in mCRC patients, the duration of
response is often limited and is only seen in a subset of patients
(Schrag, 2004). In addition, there has been no clear association
between the expression levels of EGFR in the tumours determined
by the FDA-approved PharmDx kit or other commercial anti-
EGFR antibodies and the response to therapy or patient prognosis
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s(Cunningham et al, 2004; Schrag, 2004; Chung et al, 2005;
Bhargava et al, 2006; Derecskei et al, 2006; Hebbar et al, 2006;
Bralet et al, 2007; Buckley and Kakar, 2007; Ensinger and Sterlacci,
2008; Modjtahedi and Essapen, 2009).
The increased signalling and cellular responses via the EGFR
may be mediated by several mechanisms, including overexpression
of wild-type EGFR, overproduction of EGFR ligands, deletion of
part or all of the extracellular domain, somatic mutations of its
intracellular tyrosine kinase domain and heterodimerisation with
other members of the EGFR family (Yarden, 2001; Modjtahedi and
Essapen, 2009). For example, the type-III deletion mutant form of
EGFR (EGFRvIII) is the most common variant form of EGFR and
has been detected on both the cell surface and in the cytoplasm of
many cancer types, including colorectal, glioma, breast, ovary,
prostate and lung cancer (Olapade-Olaopa et al, 2000; Tang et al,
2000; Cunningham et al, 2005). EGFRvIII is characterised by
deletion of 267 amino acids in the external domain of the receptor,
which consequently is ligand-independent, constitutively active
and highly transforming (Sugawa et al, 1990; Wong et al, 1992).
In addition, several useful anti-EGFRvIII-specific mAbs have been
developed for investigating expression levels, subcellular location,
biological and prognostic significance, predictive value, as well as
for targeting human cancers (Wikstrand et al, 1995; Omidfar et al,
2004; Heimberger et al, 2005; Gupta et al, 2010). Unfortunately,
antibodies that are used in the immunohistochemical detection
of EGFR and determining its prognostic significance and
predictive value are not specific to the wild-type EGFR and can
also bind to the EGFRvIII (Modjtahedi and Essapen, 2009). To our
knowledge, there is currently no comprehensive study examining
the expression pattern, prognostic significance and predictive
value of the wild-type EGFR protein with mAbs, which discrimi-
nate against the common EGFRvIII mutant. Such studies may lead
to identification of a more defined subpopulation of CRC patients
whose tumours are EGFR-dependent and may therefore be more
sensitive to therapy with the EGFR-blocking antibodies (Meropol,
2005; Khambata-Ford et al, 2007; Modjtahedi and Essapen, 2009).
We have extensively profiled our unique panel of high affinity
rat anti-EGFR mAbs for use in the diagnosis and therapy of human
cancers (Modjtahedi et al, 1993, 2003; Dean et al, 1994). In this
study, we investigated the potential of some of our antibodies
(ICR9, ICR10, ICR16) for immunohistochemical diagnosis of the
wild-type EGFR and/or the EGFRvIII in formalin-fixed, paraffin-
embedded human tumour specimens. We show that unlike the
antibody in the EGFR PharmDx kit, mAbs ICR10 and ICR9 are
specific for the wild-type EGFR, and therefore, these antibodies
may form ideal tools for investigating the expression pattern,
prognostic significance and predictive value of wild-type EGFR
protein in human cancers.
MATERIALS AND METHODS
Tumour cell lines and cell culture
The human EGFR-overexpressing head and neck HN5 (1.4 10
7
EGFRs per cell) and breast carcinoma cell line MCF-7, which
expresses undetectable levels of EGFR and EGFRvIII, were cultured
routinely in Dulbecco’s modified Eagle’s medium (DMEM; Sigma,
Poole, UK) supplemented with 10% fetal calf serum (Invitrogen,
Loughborough, UK) and the antibiotics penicillin, streptomycin,
neomycin as described previously (Cowley et al, 1984; Modjtahedi
et al, 1993). As human cancer cell lines show loss of EGFRvIII
expression under cell culture conditions (Lammering et al, 2004),
HC2 20d2/c was generated by transfection of NIH3T3 cells with
cDNA encoding EGFRvIII, and these cells were employed as
EGFRvIII-positive tumour (B2 10
6 mutant receptors) cell line
(Moscatello et al, 1995). HC2 20d2/c cells were maintained in
DMEM supplemented with 10% fetal calf serum and 350mgml
 1
Geneticin (Invitrogen) as described previously (Moscatello
et al, 1995). The paraffin-embedded primary human glioblastoma
(GBM) tumour slides were acquired from the Neuropathology
division of Stanford Medical Centre, with all patient identification
removed.
Antibodies
The three anti-EGFR mAbs used in this study (ICR9, ICR10 and
ICR16) were raised against three epitope clusters on the extracellular
domain of the human EGFR, using the human head and neck
carcinoma cell line HN5 as a source of immunogen (Modjtahedi
et al, 1993). ICR9 binds to epitope ‘A’, ICR10 binds to epitope ‘B’,
and ICR16 binds to epitope ‘C’ on the EGFR, respectively
(Modjtahedi et al, 1993, 2003; Dean et al, 1994). The EGFR
PharmDx kit, containing positive and negative control cell lines, was
purchased from Dako. The mouse anti-human EGFRvIII mAb G100
was purchased from Zymed Life Technologies (Grand Island, NY,
USA). The rabbit anti-rat HRP secondary antibody and FITC-
conjugated F(ab0)2 goat anti-rat IgG secondary antibody was
purchased from ABD Serotec Ltd (Oxford, UK).
Flow cytometry
The cell surface expression of the growth factor receptors was
determined using FACS analysis as described previously
(Khelwatty et al, 2011). Briefly, approximately 1 10
6 HN5 or
HC2 20d2/c cells in 1ml of DMEM/2% FBS were incubated with
primary antibodies or control medium or for 1h by rotation at
41C. Cells were washed three times by centrifugation for 5min at
1000r.p.m., and resuspended in DMEM/2% FBS before incubation
with FITC-conjugated F(ab0)2 goat anti-rat IgG secondary anti-
body. Following rotation for 1h at 41C, tumour cells were washed
three more times, and the final cell pellet was resuspended in FACS
Flow buffer (Becton Dickinson Ltd, Oxford, UK). A minimum of
10000 events were recorded by excitation with an argon laser at
488nm, and analysed using the FL-1 detector (FITC detector;
525nm) of a BD FACScalibur flow cytometer (Becton Dickinson
Ltd) using CellQuest Pro software (Becton Dickinson Ltd).
Cell pellet preparation, specimen fixation and
paraffin embedding
Cells were grown to near confluence in 170-cm
2 Nunc cell-culture
flask as described above. The cell monolayer were detached by a
cell scraper, transferred to a volumetric tube and centrifuged at
1600r.p.m. for 5min. The resultant pellet was then fixed in 10%
(v/v) neutral buffered formalin (Bios Europe Ltd, Skelmersdale,
UK) for 45min. Sequentially, the pellet was dehydrated in a series
of alcohols and cleared in histoclear, and then paraffin embedded
(Paramat, VWR International Ltd, East Grinstead, UK). Tissue
specimens were cut into sections of 5mm and mounted onto poly-
L-lysine-coated slides (Polysine, 631-0107, VWR International Ltd)
for immunohistochemistry.
EGFR PharmDx immunohistochemical staining
EGFR PharmDx immunohistochemical staining was carried out
manually according to the manufacturer’s (Dako) protocol. Briefly,
before staining, slides were deparaffinised and rehydrated. Protein K
proteolytic digestion was then carried out and endogenous activity
was blocked. Subsequently, slides were treated with primary
antibody or negative-control reagent and incubated for 30min in
a humid chamber. After rinsing in wash buffer, the slides were then
treated with labelled polymer, HRP, according to the manufacturer’s
instructions. Finally, the slides were treated with diaminobenzidine
substrate-chromogen solution (Dako), followed by counterstaining
with haematoxylin and mounting in DPX mounting medium.
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As before, the slides were deparaffinised in histoclear and
rehydrated in series of graded alcohols. The endogenous peroxi-
dase activity was then blocked by incubation in 3% hydrogen
peroxide. Non-specific binding was blocked by incubating the slides
in normal rabbit serum for 20min in a humidity chamber. After
blotting off the excess serum, each slide was incubated with 100ml
primary antibody or TBS for 1h at room temperature. Slides were
then rinsed with TBS and incubated with rabbit anti-rat antibody
HRP secondary antibody for 30min at room temperature. Finally,
the slides were treated with diaminobenzidine substrate-chromogen
solution, followed by counterstaining with haematoxylin and
mounting in DPX mounting fluid.
RESULTS
The anti-EGFR antibody clone 2-18C9 from the FDA-approved
EGFR PharmDx kit was used for immunohistochemical staining of
the human head and neck carcinoma cell line HN5 pellet (1.4 10
7
wild-type EGFR per cell) and HC2 20d2/c (1.2 10
6 EGFRvIII per
cell) cell pellets. As shown in Figure 1, the antibody in the EGFR
PharmDx kit binds strongly to both wild-type EGFR on HN5 cells
and EGFRvIII on HC2 20d2/c cells in formalin-fixed, paraffin-
embedded sections. There was no staining of EGFR-negative
CAMA-1 cells with antibody clone 2-18C9 (data not shown).
Next, we performed immunohistochemical staining of HN5 and
HC2 20d2/c cell pellets using three rat anti-EGFR mAbs: ICR9,
ICR10 and ICR16 (Modjtahedi et al, 1993, 2003). Unlike the anti-
EGFR antibody 2-18C9 in the EGFR PharmDx kit (Figure 1), mAbs
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Figure 1 Immunohistochemical staining of formalin-fixed, paraffin-embedded HN5 and HC2 20d2/c cells, using the EGFR PharmDx primary antibody
Clone 2-18C9 and negative control. EGFR staining was carried out manually according to the manufacturer’s (Dako) protocol.
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Figure 2 Immunohistochemical staining of formalin-fixed, paraffin-embedded HN5 and HC2 20d2/c cell pellets, using our anti-EGFR mAbs ICR10, ICR9
and ICR16, and negative control, as described in the ‘Materials and Methods’ section.
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stain the EGFRvIII in formalin-fixed, paraffin-embedded tumour
specimens (Figure 2). However, like antibody clone 2-18C9, mAb
ICR16 stained both HN5 and HC2 20d2/c cells and can therefore be
used for immunohistochemical detection of both wild-type EGFR
and EGFRvIII in paraffin-embedded fixed tissues (Figure 2). The
specificity of ICR10 for the wild-type EGFR was also demonstrated
by flow cytometry and the results as presented in Table 1.
Finally, we examined the diagnostic potential of mAb ICR10 for
immunohistochemical detection of wild-type EGFR in formalin-
fixed, paraffin-embedded tissue. We stained tissue from a tumour
that was EGFRvIII positive, but wild-type EGFR-negative with ICR10
and an antibody specific for EGFRvIII (G100; Figure 3). This
revealed staining by the G100, but not the ICR10. On the other hand,
using these same antibodies to stain a tumour that is EGFRvIII-
negative but wild-type EGFR-positive showed labelling of the tumour
by ICR10, but not G100. These results demonstrate that ICR10 can be
used to specifically label wild-type EGFR in pathology specimens.
DISCUSSION
Despite the approval of several EGFR inhibitors for the treatment
of human cancers, there has been no clear association between the
expression levels of EGFR in the tumours determined by the FDA-
approved EGFR PharmDx kit (Dako) or other standard anti-EGFR
antibodies and the response to the EGFR inhibitors (Arteaga, 2002;
Cunningham et al, 2004; Chung et al, 2005; Tos and Ellis, 2005;
Derecskei et al, 2006; Hebbar et al, 2006; Bralet et al, 2007; Buckley
and Kakar, 2007; Modjtahedi and Essapen, 2009; Hecht et al, 2010).
In some studies, the presence of somatic mutations of KRAS,
BRAF, PI3KCA and loss of PTEN in tumours (i.e., EGFR-
independent tumours) were associated with primary resistance,
whereas other studies found an association between the EGFR gene
amplification, high levels of EGFR ligands such as amphiregulin
and epiregulin, and sensitivity to therapy with anti-EGFR mAbs
(Amado et al, 2008; Cappuzzo et al, 2008; Di Nicolantonio et al,
2008; Jacobs et al, 2009; Modjtahedi and Essapen, 2009; Bardelli
and Siena, 2010; De Roock et al, 2010; Oliveras-Ferraros et al,
2010). Of all the markers, only KRAS genotyping is performed
routinely to exclude patients, whose tumours contain KRAS
mutations, from receiving anti-EGFR therapy (Allegra et al, 2009;
Siena et al, 2009). In addition, clinical benefit is not seen in all
mCRC patients with wild-type KRAS, and there is a need for the
identification of more reliable predictive markers for use in the
selection of patients whose tumours are EGFR-dependent and will
therefore benefit from therapy with EGFR-blocking antibodies.
In CRC, the percentage of EGFR-positive cases reported in the
literature ranged from 8 to 100% of the cases examined. In
addition, there are also conflicting data regarding the correlation
between the EGFR protein expression in the primary tumour and
its related metastases, and their prognostic significance and
predictive value (Scartozzi et al, 2004; Chung et al, 2005; Ljuslinder
et al, 2009). This wide variation may be due to the usage of
different antibodies, tumour specimen source (e.g., primary
tumour and/or related metastasis), scoring system, choice of
fixative, storage time and patient subpopulations (Atkins et al,
2004; Scartozzi et al, 2004; Cunningham et al, 2005; Meropol, 2005;
Perez-Soler and Saltz, 2005; Hebbar et al, 2006; Penault-Llorca
et al, 2006; Bralet et al, 2007; Buckley and Kakar, 2007; Ljuslinder
et al, 2009; Modjtahedi and Essapen, 2009; Bardelli and Siena,
2010; Yarom et al, 2010). In addition, antibodies which are
EGFRvIII+/wt EGFR– GBM EGFRvIII–/wt EGFR+ GBM
G100
ICR10
50m 50m
50m
Figure 3 Differential staining of tumours containing wild-type EGFR vs EGFRvIII by ICR10. A primary human glioblastoma tumour positive for EGFRvIII,
but lacking EGFR expression (EGFRvIIIþ/wt EGFR GBM) was stained by immunohistochemistry using either G100 (specific for EGFRvIII only) or ICR10.
A second glioblastoma tumour that was negative for EGFRvIII, but positive for wt EGFR (EGFRvIII /wt EGFRþ) was also stained with G100 and ICR10.
Table 1 MFI for binding of anti-EGFR mAbs ICR10 and ICR16 to the EGFR-
overexpressing HN5 and EGFRvIII-overexpressing (HC2 20d2/c) cell lines
MFI
Antibody HN5 HC220d2/c
Control 6.87 5.04
ICR10 1092.45 3.55
ICR16 1189.75 593.05
Abbreviations: EGFR¼epidermal growth factor receptor; EGFRvIII¼type-III deletion
mutant form of EGFR; mAbs¼monoclonal antibodies; MFI¼mean fluorescence
intensity.
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to determine its prognostic significance and predictive value for
response to therapy with the EGFR inhibitors are not specific to
the wild-type EGFR and can also bind to the EGFRvIII. Indeed, in
this study, we have shown that the FDA-approved antibody in the
EGFR PharmDx kit (Dako), which is used in the selection of EGFR-
positive cancer patients for therapy with anti-EGFR mAbs, is not
specific to the wild-type EGFR protein and can also bind to the
EGFRvIII in formalin-fixed, paraffin-embedded tissues (Figure 1).
Our anti-EGFR mAb ICR16 can also bind to both EGFR and
EGFRvIII in formalin-fixed, paraffin-embedded tissues. We have
reported previously that in comparison with mAbs ICR9 and
ICR10, mAb ICR16 was very effective in (1) blocking the binding of
ligands to the EGFR, (2) inhibiting the tyrosine phosphorylation of
EGFR and downstream cell signalling molecules, and (3) inhibiting
the growth of in vitro and in vivo of EGFR-overexpressing
tumour cell lines (Modjtahedi et al, 1993, 2003; Dean et al, 1994;
Modjtahedi and Dean, 1994). Interestingly, unlike mAbs clone
2-18C9 and ICR16, we have shown here that mAbs ICR10 and ICR9
are specific for the wild-type EGFR and can therefore be used for
immunohistochemical detection of wild-type EGFR in formalin-
fixed, paraffin-embedded tissues (Figures 1–3).
In summary, at present, eligible patients for therapy with
cetuximab and panitumumab, in addition to wild-type KRAS,
should express cell surface EGFR in their tumours, using the FDA-
approved Dako EGFR PharmDx immunohistochemistry kit or
other anti-EGFR antibodies. However, such antibodies do not
discriminate between the ligand-independent and constitutively
active EGFRvIII, and wild-type EGFR and somatic mutation of the
EGFR intracellular tyrosine kinase domain is rare in patients with
mCRC (Lee et al, 2005). We conclude that mAbs ICR9 and ICR10
are ideal tools for investigating the expression level and the
cellular location of wild-type EGFR in formalin-fixed, paraffin-
embedded tumour specimens using immunohistochemistry, and
to unravel its prognostic significance as well as predictive value for
response to therapy with the EGFR-blocking antibodies in future
studies.
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